167 related articles for article (PubMed ID: 27595689)
1. Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
Bhatnagar A; Bolli R; Johnstone BH; Traverse JH; Henry TD; Pepine CJ; Willerson JT; Perin EC; Ellis SG; Zhao DX; Yang PC; Cooke JP; Schutt RC; Trachtenberg BH; Orozco A; Resende M; Ebert RF; Sayre SL; Simari RD; Moyé L; Cogle CR; Taylor DA;
Am Heart J; 2016 Sep; 179():142-50. PubMed ID: 27595689
[TBL] [Abstract][Full Text] [Related]
2. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
Traverse JH; Henry TD; Ellis SG; Pepine CJ; Willerson JT; Zhao DX; Forder JR; Byrne BJ; Hatzopoulos AK; Penn MS; Perin EC; Baran KW; Chambers J; Lambert C; Raveendran G; Simon DI; Vaughan DE; Simpson LM; Gee AP; Taylor DA; Cogle CR; Thomas JD; Silva GV; Jorgenson BC; Olson RE; Bowman S; Francescon J; Geither C; Handberg E; Smith DX; Baraniuk S; Piller LB; Loghin C; Aguilar D; Richman S; Zierold C; Bettencourt J; Sayre SL; Vojvodic RW; Skarlatos SI; Gordon DJ; Ebert RF; Kwak M; Moyé LA; Simari RD;
JAMA; 2011 Nov; 306(19):2110-9. PubMed ID: 22084195
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.
Schutt RC; Trachtenberg BH; Cooke JP; Traverse JH; Henry TD; Pepine CJ; Willerson JT; Perin EC; Ellis SG; Zhao DX; Bhatnagar A; Johnstone BH; Lai D; Resende M; Ebert RF; Wu JC; Sayre SL; Orozco A; Zierold C; Simari RD; Moyé L; Cogle CR; Taylor DA;
Circ Res; 2015 Jan; 116(1):99-107. PubMed ID: 25406300
[TBL] [Abstract][Full Text] [Related]
4. Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.
Contreras A; Orozco AF; Resende M; Schutt RC; Traverse JH; Henry TD; Lai D; Cooke JP; Bolli R; Cohen ML; Moyé L; Pepine CJ; Yang PC; Perin EC; Willerson JT; Taylor DA;
Basic Res Cardiol; 2017 Jan; 112(1):3. PubMed ID: 27882430
[TBL] [Abstract][Full Text] [Related]
5. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.
Cogle CR; Wise E; Meacham AM; Zierold C; Traverse JH; Henry TD; Perin EC; Willerson JT; Ellis SG; Carlson M; Zhao DX; Bolli R; Cooke JP; Anwaruddin S; Bhatnagar A; da Graca Cabreira-Hansen M; Grant MB; Lai D; Moyé L; Ebert RF; Olson RE; Sayre SL; Schulman IH; Bosse RC; Scott EW; Simari RD; Pepine CJ; Taylor DA;
Circ Res; 2014 Oct; 115(10):867-74. PubMed ID: 25136078
[TBL] [Abstract][Full Text] [Related]
6. Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease.
Turan RG; Bozdag-Turan I; Ortak J; Akin I; Kische S; Schneider H; Turan CH; Rehders TC; Rauchhaus M; Kleinfeldt T; Adolph E; Brehm M; Yokus S; Steiner S; Sahin K; Nienaber CA; Ince H
Stem Cells Dev; 2011 Sep; 20(9):1491-501. PubMed ID: 21190450
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction.
Turan RG; Brehm M; Koestering M; Tobias Z; Bartsch T; Steiner S; Picard F; Ebner P; Schannwell CM; Strauer BE
Eur J Clin Invest; 2007 Nov; 37(11):842-51. PubMed ID: 17973780
[TBL] [Abstract][Full Text] [Related]
8. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial.
Nasseri BA; Ebell W; Dandel M; Kukucka M; Gebker R; Doltra A; Knosalla C; Choi YH; Hetzer R; Stamm C
Eur Heart J; 2014 May; 35(19):1263-74. PubMed ID: 24497345
[TBL] [Abstract][Full Text] [Related]
9. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.
Mansour S; Roy DC; Bouchard V; Nguyen BK; Stevens LM; Gobeil F; Rivard A; Leclerc G; Reeves F; Noiseux N
J Cardiovasc Transl Res; 2010 Apr; 3(2):153-9. PubMed ID: 20560029
[TBL] [Abstract][Full Text] [Related]
10. Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133
Bassetti B; Carbucicchio C; Catto V; Gambini E; Rurali E; Bestetti A; Gaipa G; Belotti D; Celeste F; Parma M; Righetti S; Biava L; Arosio M; Bonomi A; Agostoni P; Scacciatella P; Achilli F; Pompilio G
Stem Cell Res Ther; 2018 Sep; 9(1):235. PubMed ID: 30217223
[TBL] [Abstract][Full Text] [Related]
11. CD45
Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
[TBL] [Abstract][Full Text] [Related]
12. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
Traverse JH; Henry TD; Pepine CJ; Willerson JT; Zhao DX; Ellis SG; Forder JR; Anderson RD; Hatzopoulos AK; Penn MS; Perin EC; Chambers J; Baran KW; Raveendran G; Lambert C; Lerman A; Simon DI; Vaughan DE; Lai D; Gee AP; Taylor DA; Cogle CR; Thomas JD; Olson RE; Bowman S; Francescon J; Geither C; Handberg E; Kappenman C; Westbrook L; Piller LB; Simpson LM; Baraniuk S; Loghin C; Aguilar D; Richman S; Zierold C; Spoon DB; Bettencourt J; Sayre SL; Vojvodic RW; Skarlatos SI; Gordon DJ; Ebert RF; Kwak M; Moyé LA; Simari RD;
JAMA; 2012 Dec; 308(22):2380-9. PubMed ID: 23129008
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial.
Tendera M; Wojakowski W; Ruzyłło W; Chojnowska L; Kepka C; Tracz W; Musiałek P; Piwowarska W; Nessler J; Buszman P; Grajek S; Breborowicz P; Majka M; Ratajczak MZ;
Eur Heart J; 2009 Jun; 30(11):1313-21. PubMed ID: 19208649
[TBL] [Abstract][Full Text] [Related]
14. Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
Taylor DA; Perin EC; Willerson JT; Zierold C; Resende M; Carlson M; Nestor B; Wise E; Orozco A; Pepine CJ; Henry TD; Ellis SG; Zhao DX; Traverse JH; Cooke JP; Schutt RC; Bhatnagar A; Grant MB; Lai D; Johnstone BH; Sayre SL; Moyé L; Ebert RF; Bolli R; Simari RD; Cogle CR;
Cell Transplant; 2016; 25(9):1675-1687. PubMed ID: 26590374
[TBL] [Abstract][Full Text] [Related]
15. Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.
Lamirault G; Susen S; Forest V; Hemont C; Parini A; Le Corvoisier P; Piot C; Richard MJ; Delasalle B; Rouard H; Sportouch C; Persoons V; Van Belle E; Roncalli J; Lemarchand P
Stem Cell Res Ther; 2013; 4(6):152. PubMed ID: 24423369
[TBL] [Abstract][Full Text] [Related]
16. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Traverse JH; Henry TD; Vaughan DE; Ellis SG; Pepine CJ; Willerson JT; Zhao DX; Simpson LM; Penn MS; Byrne BJ; Perin EC; Gee AP; Hatzopoulos AK; McKenna DH; Forder JR; Taylor DA; Cogle CR; Baraniuk S; Olson RE; Jorgenson BC; Sayre SL; Vojvodic RW; Gordon DJ; Skarlatos SI; Moyè LA; Simari RD;
Tex Heart Inst J; 2010; 37(4):412-20. PubMed ID: 20844613
[TBL] [Abstract][Full Text] [Related]
17. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis.
Delewi R; Hirsch A; Tijssen JG; Schächinger V; Wojakowski W; Roncalli J; Aakhus S; Erbs S; Assmus B; Tendera M; Goekmen Turan R; Corti R; Henry T; Lemarchand P; Lunde K; Cao F; Huikuri HV; Sürder D; Simari RD; Janssens S; Wollert KC; Plewka M; Grajek S; Traverse JH; Zijlstra F; Piek JJ
Eur Heart J; 2014 Apr; 35(15):989-98. PubMed ID: 24026778
[TBL] [Abstract][Full Text] [Related]
18. Timing of bone marrow cell delivery has minimal effects on cell viability and cardiac recovery after myocardial infarction.
Swijnenburg RJ; Govaert JA; van der Bogt KE; Pearl JI; Huang M; Stein W; Hoyt G; Vogel H; Contag CH; Robbins RC; Wu JC
Circ Cardiovasc Imaging; 2010 Jan; 3(1):77-85. PubMed ID: 19920031
[TBL] [Abstract][Full Text] [Related]
19. Distinct mobilization of circulating CD271+ mesenchymal progenitors from hematopoietic progenitors during aging and after myocardial infarction.
Iso Y; Yamaya S; Sato T; Poole CN; Isoyama K; Mimura M; Koba S; Kobayashi Y; Takeyama Y; Spees JL; Suzuki H
Stem Cells Transl Med; 2012 Jun; 1(6):462-8. PubMed ID: 23197850
[TBL] [Abstract][Full Text] [Related]
20. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis.
Traverse JH; Henry TD; Pepine CJ; Willerson JT; Chugh A; Yang PC; Zhao DXM; Ellis SG; Forder JR; Perin EC; Penn MS; Hatzopoulos AK; Chambers JC; Baran KW; Raveendran G; Gee AP; Taylor DA; Moyé L; Ebert RF; Simari RD
Circ Res; 2018 Feb; 122(3):479-488. PubMed ID: 29208679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
